secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0000950170-23-009543
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx board director Lars Ekman to retire after 2023 annual meeting
------------------------------------------------------------------------

- Lars Ekman, M.D., Ph.D. will retire from the Board effective immediately after the 2023 Annual Meeting on June 7, 2023.
- Retirement is for personal reasons and not related to any disagreement with the Company or management.
- No replacement director has been announced as of the filing date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023009543/0000950170-23-009543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023009543/rare-20230320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer